Q2 2026 saw record revenues exceeding $950 million, driven by strong performances from INGREZZA, CRENESSITY, and the newly acquired VYKAT XR. Guidance for INGREZZA was raised, and the company remains on track for key clinical milestones in 2027, with robust financial flexibility and expanding market presence.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.